Roche partners with Defand Therapeutics to discover molecular glue drugs for cancer and immune diseases
Roche and Defand enter molecular glue discovery collaboration targeting cancer and immune-mediated diseases
Roche has entered a drug-discovery collaboration with China-based Defand Therapeutics focused on developing molecular glue medicines for oncology and immune-mediated diseases.
The agreement highlights growing pharmaceutical interest in targeted protein degradation and Chinese biotechnology innovation, although the companies have not publicly confirmed the financial terms.
Field | Content |
Alert Type | Deals |
Companies | Roche; Defand Therapeutics |
Deal Type | Research and drug-discovery collaboration |
Asset or Company | Molecular glue drug-discovery programmes |
Therapy Area(s) | Oncology; immune-mediated diseases |
Technology or Modality | Molecular glue therapeutics; targeted protein degradation |
Deal Value | Financial terms not publicly disclosed; reported potential value approaching $1bn remains unconfirmed |
Development Stage (if relevant) | Discovery and research |
Geography | Switzerland; China |
What Happened | Roche and Defand Therapeutics entered a collaboration to discover and develop molecular glue medicines targeting cancer and immune-mediated diseases. |
Why It Matters | The agreement demonstrates pharmaceutical interest in molecular glue technology and the growing role of Chinese biotechnology companies in international drug-discovery partnerships. |
Supporting Context | Molecular glues are small molecules designed to promote interactions between proteins, potentially enabling the degradation of disease-associated targets. |
Strategic Rationale (optional) | The collaboration provides Roche with access to Defand's molecular glue discovery capabilities while supporting the international development of Defand's technology. |
Potential Impact (optional) | Successful research could generate drug candidates against disease-associated proteins that have historically been difficult to target. |
Key Takeaway | Roche's collaboration with Defand adds to pharmaceutical investment in molecular glue drug discovery and cross-border biotechnology partnerships. |
What to Watch (optional) | Further disclosure of financial terms, nominated drug candidates and progression into preclinical development. |
Primary Source | https://www.statnews.com/2026/10/08/roche-defand-therapeutics-drug-development-deal/ |
Relevant Date | 8 October 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com
Comentarios